仙琚制药
(002332)
| 流通市值：86.55亿 | | | 总市值：86.85亿 |
| 流通股本：9.86亿 | | | 总股本：9.89亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,928,372,588.69 | 1,958,633,864.22 | 918,349,166.84 | 3,758,969,165.42 |
| 营业收入 | 2,928,372,588.69 | 1,958,633,864.22 | 918,349,166.84 | 3,758,969,165.42 |
| 二、营业总成本 | 2,470,176,318.76 | 1,634,971,949.57 | 810,954,601.33 | 3,292,197,358.83 |
| 营业成本 | 1,120,126,544.26 | 741,332,189.74 | 372,237,605.31 | 1,458,967,954.93 |
| 税金及附加 | 29,509,398.04 | 21,233,277.19 | 7,161,090.74 | 39,503,429.87 |
| 销售费用 | 886,571,935.41 | 586,194,417.41 | 284,470,963.24 | 1,180,436,455.03 |
| 管理费用 | 251,067,977.15 | 160,346,123.89 | 74,372,386.44 | 317,390,102.15 |
| 研发费用 | 175,565,831.68 | 120,531,295.05 | 69,002,590.89 | 303,747,966.62 |
| 财务费用 | 7,334,632.22 | 5,334,646.29 | 3,709,964.71 | -7,848,549.77 |
| 其中:利息费用 | 2,602,103.65 | 1,351,468.79 | 725,412.82 | 4,644,527.08 |
| 其中:利息收入 | 9,674,711.35 | 6,315,420.79 | 2,323,060.26 | 16,726,364.65 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -14,545,906.22 | -9,103,331.92 | -5,571,904.07 | -26,411,420.79 |
| 资产处置收益 | -225,924.28 | -107,128.87 | -114,585.32 | 46,299,441.47 |
| 资产减值损失(新) | -31,678,725.92 | -31,701,884.15 | - | -38,213,637.37 |
| 信用减值损失(新) | -2,294,107.5 | -5,867,243.27 | -2,067,376.63 | -7,289,272.83 |
| 其他收益 | 24,916,616.27 | 16,261,729.77 | 9,791,499.58 | 31,201,581.31 |
| 四、营业利润 | 434,368,222.28 | 293,144,056.21 | 109,432,199.07 | 472,358,498.38 |
| 加:营业外收入 | 82,646,531.78 | 77,991.07 | 9,253.7 | 72,978,072.14 |
| 减:营业外支出 | 12,608,033 | 3,474,786.52 | 1,138,779.56 | 9,495,517.39 |
| 五、利润总额 | 504,406,721.06 | 289,747,260.76 | 108,302,673.21 | 535,841,053.13 |
| 减:所得税费用 | 85,740,783.91 | 45,162,080.7 | 17,934,135.59 | 83,237,392.57 |
| 六、净利润 | 418,665,937.15 | 244,585,180.06 | 90,368,537.62 | 452,603,660.56 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 418,665,937.15 | 244,585,180.06 | 90,368,537.62 | 452,603,660.56 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 422,214,882.68 | 244,553,022.38 | 93,886,296.97 | 449,640,395.37 |
| 少数股东损益 | -3,548,945.53 | 32,157.68 | -3,517,759.35 | 2,963,265.19 |
| 扣除非经常损益后的净利润 | 361,094,900.64 | 241,943,736.47 | 90,112,023.4 | 348,698,522.73 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.43 | 0.25 | 0.09 | 0.45 |
| (二)稀释每股收益 | 0.43 | 0.25 | 0.09 | 0.45 |
| 八、其他综合收益 | -113,218,605.54 | -84,440,890.22 | -50,090,940.43 | 127,106,783.52 |
| 归属于母公司股东的其他综合收益 | -113,218,605.54 | -84,440,890.22 | -50,090,940.43 | 127,106,783.52 |
| 九、综合收益总额 | 305,447,331.61 | 160,144,289.84 | 40,277,597.19 | 579,710,444.08 |
| 归属于母公司股东的综合收益总额 | 308,996,277.14 | 160,112,132.16 | 43,795,356.54 | 576,747,178.89 |
| 归属于少数股东的综合收益总额 | -3,548,945.53 | 32,157.68 | -3,517,759.35 | 2,963,265.19 |
| 公告日期 | 2026-10-26 | 2026-08-28 | 2026-04-28 | 2026-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |